29 research outputs found
Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells
ABSTRACT The triple-negative breast cancer (TNBC) subtype is enriched in cancer stem cells (CSCs) and clinically correlated with the highest rate of recurrence. Several studies implicate the RSK pathway as being pivotal for the growth and proliferation of CSCs, which are postulated to drive tumor relapse. We now address the potential for the newly developed RSK inhibitor LJI308 to target the CSC population and repress TNBC growth and dissemination. Overexpression of the Y-box binding protein-1 (YB-1) oncogene in human mammary epithelial cells (HMECs) drove TNBC tumor formation characterized by a multi-drug resistance phenotype, yet these cells were sensitive to LJI308 in addition to the classic RSK inhibitors BI-D1870 and luteolin. Notably, LJI308 specifically targeted transformed cells as it had little effect on the non-tumorigenic parental HMECs. Loss of cell growth, both in 2D and 3D culture, was attributed to LJI308-induced apoptosis. We discovered CD44+/CD49f+ TNBC cells to be less sensitive to chemotherapy compared to the isogenic CD44-/CD49f-cells. However, inhibition of RSK using LJI308, BI-D1870, or luteolin was sufficient to eradicate the CSC population. We conclude that targeting RSK using specific and potent inhibitors, such as LJI308, delivers the promise of inhibiting the growth of TNBC
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition
Malignant peripheral nerve sheath tumours (MPNST) are rare, hereditary cancers associated with neurofibromatosis type I. MPNSTs lack effective treatment options as they often resist chemotherapies and have high rates of disease recurrence. Aurora kinase A (AURKA) is an emerging target in cancer and an aurora kinase inhibitor (AKI), termed MLN8237, shows promise against MPNST cell lines in vitro and in vivo. Here, we test MLN8237 against two primary human MPNST grown in vivo as xenotransplants and find that treatment results in tumour cells exiting the cell cycle and undergoing endoreduplication, which cumulates in stabilized disease. Targeted therapies can often fail in the clinic due to insufficient knowledge about factors that determine tumour susceptibilities, so we turned to three MPNST cell-lines to further study and modulate the cellular responses to AKI. We find that the sensitivity of cell-lines with amplification of AURKA depends upon the activity of the kinase, which correlates with the expression of the regulatory gene products TPX2 and HMMR/RHAMM. Silencing of HMMR/RHAMM, but not TPX2, augments AURKA activity and sensitizes MPNST cells to AKI. Furthermore, we find that AURKA activity is critical to the propagation and self-renewal of sphere-enriched MPNST cancer stem-like cells. AKI treatment significantly reduces the formation of spheroids, attenuates the self-renewal of spheroid forming cells, and promotes their differentiation. Moreover, silencing of HMMR/RHAMM is sufficient to endow MPNST cells with an ability to form and maintain sphere culture. Collectively, our data indicate that AURKA is a rationale therapeutic target for MPNST and tumour cell responses to AKI, which include differentiation, are modulated by the abundance of HMMR/RHAMM
Discovery of cellular regulation by protein degradation
What follows is a story of some of the lab’s adventures mentioned above, including the inventions of new biochemical and genetic methods. This account stems, in part, from previous descriptions of the early history of the Ub field (31,32). Another antecedent is an interview I gave to Dr. Istvan Hargittai, a distinguished Hungarian chemist. It describes my life and science, including the early years in Moscow, the 1977 escape from the former Soviet Union, the essentially accidental hiring of me by MIT, and the work that ensued (33). The narrative below borrows from these sources, and mentions our more recent contributions as well
Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice
Recent studies have begun to reveal critical roles of microRNAs (miRNAs) in the pathogenesis of cardiac hypertrophy and dysfunction. In this study, we tested whether a transforming growth factor-β (TGF-β)-regulated miRNA played a pivotal role in the development of cardiac hypertrophy and heart failure (HF). We observed that miR-27b was upregulated in hearts of cardiomyocyte-specific Smad4 knockout mice, which developed cardiac hypertrophy. In vitro experiments showed that the miR-27b expression could be inhibited by TGF-β1 and that its overexpression promoted hypertrophic cell growth, while the miR-27b suppression led to inhibition of the hypertrophic cell growth caused by phenylephrine (PE) treatment. Furthermore, the analysis of transgenic mice with cardiomyocyte-specific overexpression of miR-27b revealed that miR-27b overexpression was sufficient to induce cardiac hypertrophy and dysfunction. We validated the peroxisome proliferator-activated receptor-γ (PPAR-γ) as a direct target of miR-27b in cardiomyocyte. Consistently, the miR-27b transgenic mice displayed significantly lower levels of PPAR-γ than the control mice. Furthermore, in vivo silencing of miR-27b using a specific antagomir in a pressure-overload-induced mouse model of HF increased cardiac PPAR-γ expression, attenuated cardiac hypertrophy and dysfunction. The results of our study demonstrate that TGF-β1-regulated miR-27b is involved in the regulation of cardiac hypertrophy, and validate miR-27b as an efficient therapeutic target for cardiac diseases
In vitro and in vivo characterization of a small-colony variant of the primary form of photorhabdus luminescens MD (Enterobacteriaceae)
Nematicidal metabolites produced by Photorhabdus luminescens (Enterobacteriaceae), bacterial symbiont of entomopathogenic nematodes
YB-1 enhances ABCG2 expression in breast cancer to elicit chemoresistance that can be circumvented using RSK inhibitors
Despite advances in the treatment and management of breast cancer, recurrence remains a significant problem. Current dogma dictates that populations of drug resistant cells within a heterogeneous tumour are responsible for relapse. In this study, we demonstrate that the oncogenic transcription factor Y-box binding protein-1 (YB-1) regulates the expression of ABCG2, an ATP-binding transporter involved in multidrug resistance. Introducing YB-1 into human mammary epithelial cells (HMECs) was associated with increased ABCG2 promoter acetylation and gene expression. Accordingly, these cells acquired resistance to chemotherapeutic substrates of ABCG2, notably 5-fluoruracil, doxorubicin, and gefitinib. The acetylation-mediated relaxation of the ABCG2 promoter allowed for direct YB-1 binding and transcriptional regulation. As such, repressing YB-1 activation by RSK using the small molecule inhibitors BI-D1870 and luteolin led to a decrease in ABCG2 expression and resensitization of cells to chemotherapy. We found that treatment with luteolin or NVP-LJI308, a next-generation RSK inhibitor, was sufficient to induce apoptosis in triple-negative breast cancer cells. Moreover, RSK inhibition repressed soft agar colony growth and mammosphere formation. Relapse is believed to initiate from a drug resistant stem-like subpopulation within a heterogeneous tumour. Sorting for CD44+/CD49f+ cells revealed them to have an over 2-fold increase in ABCG2 expression relative to bulk tumour cells. As a result, they were refractory to traditional chemotherapy, but sensitive to the RSK inhibitors BI-D1870, NVP-LJI308, and luteolin. Therefore, targeting the RSK/YB-1 pathway inhibits ABCG2 and could represent a potential avenue to overcome multidrug resistance
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells
Introduction:
Triple-negative breast cancer (TNBC) high rate of relapse is thought to be due to the presence of tumor-initiating cells (TICs), molecularly defined as being CD44high/CD24-/low. TICs are resilient to chemotherapy and radiation. However, no currently accepted molecular target exists against TNBC and, moreover, TICs. Therefore, we sought the identification of kinase targets that inhibit TNBC growth and eliminate TICs.
Methods:
A genome-wide human kinase small interfering RNA (siRNA) library (691 kinases) was screened against the TNBC cell line SUM149 for growth inhibition. Selected siRNAs were then tested on four different breast cancer cell lines to confirm the spectrum of activity. Their effect on the CD44high subpopulation and sorted CD44high/CD24-/low cells of SUM149 also was studied. Further studies were focused on polo-like kinase 1 (PLK1), including its expression in breast cancer cell lines, effect on the CD44high/CD24-/low TIC subpopulation, growth inhibition, mammosphere formation, and apoptosis, as well as the activity of the PLK1 inhibitor, BI 2536.
Results:
Of the 85 kinases identified in the screen, 28 of them were further silenced by siRNAs on MDA-MB-231 (TNBC), BT474-M1 (ER+/HER2+, a metastatic variant), and HR5 (ER+/HER2+, a trastuzumab-resistant model) cells and showed a broad spectrum of growth inhibition. Importantly, 12 of 28 kinases also reduced the CD44high subpopulation compared with control in SUM149. Further tests of these 12 kinases directly on a sorted CD44high/CD24-/low TIC subpopulation of SUM149 cells confirmed their effect. Blocking PLK1 had the greatest growth inhibition on breast cancer cells and TICs by about 80% to 90% after 72 hours. PLK1 was universally expressed in breast cancer cell lines, representing all of the breast cancer subtypes, and was positively correlated to CD44. The PLK1 inhibitor BI 2536 showed similar effects on growth, mammosphere formation, and apoptosis as did PLK1 siRNAs. Finally, whereas paclitaxel, doxorubicin, and 5-fluorouracil enriched the CD44high/CD24-/low population compared with control in SUM149, subsequent treatment with BI 2536 killed the emergent population, suggesting that it could potentially be used to prevent relapse.
Conclusion:
Inhibiting PLK1 with siRNA or BI 2536 blocked growth of TNBCs including the CD44high/CD24-/low TIC subpopulation and mammosphere formation. Thus, PLK1 could be a potential therapeutic target for the treatment of TNBC as well as other subtypes of breast cancer.Experimental Medicine, Division ofMedical Genetics, Department ofMedicine, Department ofMedicine, Faculty ofPediatrics, Department ofOther UBCReviewedFacult
Two types of patterns of localized traveling wave convection in binary fluid mixtures with different structures
Table_2_Associations between two conceptualizations of materialism and subjective wellbeing in China: A meta-analysis of studies from 1998 to 2022.XLSX
This meta-analysis examines the relationship between materialism (materialistic values and extrinsic aspirations) and subjective wellbeing in the Chinese population. Fifty-six relevant studies covering the period from 1998 to 2022 were included in the meta-analysis. Fifty-eight independent effect sizes from a total of 52,368 participants were obtained to calculate the mean effect sizes. Materialistic values correlated with significantly lower subjective wellbeing (r = −0.205), while the mean effect size for extrinsic aspirations was found to be not significant (r = −0.048). The effect sizes varied across different types of wellbeing outcomes (materialistic values: rs = −0.095 to −0.202; extrinsic aspirations: rs = 0.066 to −0.125). The associations were also moderated by certain demographic factors (age and gender), methodological factors (study design and scoring method), publication features (type of publication and publication year), and economic indicators (economic growth and wealth inequality). We discuss our limitations and the implications for future research.</p